Streptococcus pneumoniae type 19F capsular polysaccharide diphtheria CRM197 protein conjugate antigen

DB10291ApprovedInvestigationalVaccinesInactivated Pneumococcal Vaccine

Streptococcus pneumoniae type 19F capsular polysaccharide diphtheria CRM197 protein conjugate antigen is a sterile vaccine that contains saccharides of the capsular antigens of Streptococcus pneumoniae serotype 19F individually conjugated to... It is contained in the vaccine under the market name Prevnar that contains the saccharides for serotypes 4, 6B, 9V, 14, 18C, 19F, and 23F for intramuscular injection.

First approval
United States, 2000 · European Union, 2022
Also known as
Streptococcus pneumoniae serotype 19F capsular antigen diphtheria CRM197 protein conjugate vaccine
Brand names
  • Prevnar 13
  • Prevnar 20
  • Vaxneuvance

Resolves to

Compound
UNII2E1M7F958B
Clinical / RWD
RxNorm798224

What you can answer from here — as of April 02, 2025

81Clinical trialsPhase, status and sponsor resolved per trial
Sign in
2Structured indicationsCondition, population, route and combination as fields, not prose
Sign in
28Marketed productsAcross 5 countries and 8 labellers
Sign in

Which other approved drugs treat the same conditions as Streptococcus pneumoniae type 19F capsular polysaccharide diphtheria CRM197 protein conjugate antigen, and which companies have late-stage candidates in those indications?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In